RU
Robert Uger
Chief Scientific Officer

Robert Uger insider trades: Trillium Therapeutics (TRIL) stock sales

Chief Scientific Officer, Trillium Therapeutics Last trade Jul 7, 2021 11 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2021
1
Company
last trade 2021

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Robert reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jul 7, 2021TRIL↓ Sell$33K
Jun 7, 2021TRIL↓ Sell$30K
May 7, 2021TRIL↓ Sell$34K
Apr 7, 2021TRIL↓ Sell$39K
Mar 12, 2021TRIL↓ Sell$35K
Mar 8, 2021TRIL↓ Sell$37K
Feb 9, 2021TRIL↓ Sell$91K
Jan 11, 2021TRIL↓ Sell$9K
Jan 8, 2021TRIL↓ Sell$134K
Jan 7, 2021TRIL↓ Sell$54K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Robert Uger's insider trades

Robert Uger is Chief Scientific Officer at Trillium Therapeutics (TRIL). Since Jan 7, 2021, Robert has reported no open-market purchases and 10 sales worth $496K on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include option exercises (10 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TRIL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.